[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Page 38707]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16839]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development.
    Technology description follows.

Neuroendocrine Tumor Evans Blue Containing Radiotherapeutics

    The invention pertains to a radiotherapeutic against neuroendocrine 
tumors that express somatostatin receptor. Radionuclide therapies 
directed against tumors that express somatostatin receptors (SSTRs) 
have proven effective for the treatment of advanced, low- to 
intermediate-grade neuroendocrine tumors. The subject radiotherapeutic 
covered by the subject patent estate includes a somatostatin (SST) 
peptide derivative like octreotate (TATE), conjugated to an Evans Blue 
(EB) analog, and further chelated via DOTA to therapeutic 
radionuclide\177\Lu, a beta emitter. The EB analog reversibly binds to 
circulating serum albumin and improves the pharmacokinetics of SST 
peptide derivatives and reduce peptide-receptor radionuclide therapy 
toxicity. EB analog conjugated to octreotate (EB-DOTATATE) has been 
shown by the inventors to provide reversible albumin binding in vivo 
and extended half-life in circulation. When EB-TATE is slowly released 
into the tumor microenvironment, tumor uptake and internalization into 
SSTR positive tumors resulted in delivery of radioactive particles and 
tumor cell killing. EB-TATE displayed significantly more favorable 
pharmacokinetics than TATE alone by achieving higher tumor to non-tumor 
penetration as evidenced by positron emission tomography.
    Potential Commercial Applications:

<bullet> Cancer therapeutics
<bullet> Higher stability/Lower toxicity

    Development Stage:

<bullet> Early stage

    Inventors: Xiaoyuan Chen and Orit Jacobson Weiss (both of NIBIB).
    Intellectual Property: HHS Reference No. E-150-2016-1; 
International Patent Application PCT/US2017/031696.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
<a href="/cdn-cgi/l/email-protection#14677c797d787b62795479757d783a7a7d7c3a737b62"><span class="__cf_email__" data-cfemail="dfacb7b2b6b3b0a9b29fb2beb6b3f1b1b6b7f1b8b0a9">[email protected]</span></a>.

    Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16839 Filed 8-6-18; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>